{"doi":"10.1002/cncr.33409","title":"Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission","abstract":"BACKGROUND: New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high-risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell transplantation (ASCT) will eventually relapse with poor outcomes. METHODS: In this phase 2 trial, the efficacy of lenalidomide maintenance was evaluated in patients with high-risk AML who had achieved their first or second remission after induction chemotherapy and at least 1 consolidation cycle and who were not candidates for immediate ASCT. Lenalidomide was given orally at 10 to 20 mg daily on days 1 to 28 of a 28-day cycle for up to 24 cycles. RESULTS: A total of 28 patients were enrolled in this study with a median age of 61 years (range, 24-87 years). The median number of cycles was 8 (range, 1-24 cycles). Ten patients (36%) completed 24 months of maintenance treatment. With a median follow-up of 22.5 months (range, 2.6-55 months), 12 patients (43%) relapsed after a median of 3 months (range, 0.7-23 months). The median duration of remission for all patients was 18.7 months (range, 0.7-55.1 months). The 2-year overall survival and relapse-free survival rates from the time of enrollment were 63% and 50%, respectively. Overall, lenalidomide was well tolerated; serious adverse events of grade 3 or 4, including rash (n = 5), thrombocytopenia (n = 4), neutropenia (n = 4), and fatigue (n = 2), were observed in 13 patients (46%). CONCLUSIONS: Lenalidomide is a safe and feasible maintenance strategy in patients with high-risk AML who are not candidates for ASCT, and it has beneficial effects for patients with negative measurable residual disease.","journal":"Cancer","year":2021,"id":198125,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9504,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":109598,"name":"Hagop M. Kantarjian","orcid":"0000-0002-1908-3307","position":1,"is_corresponding":false},{"id":230403,"name":"Farhad Ravandi","orcid":"0000-0002-7621-377X","position":2,"is_corresponding":false},{"id":232840,"name":"Naval Daver","orcid":"0000-0001-7103-373X","position":3,"is_corresponding":false},{"id":293088,"name":"Xuemei Wang","orcid":"0000-0002-3516-0966","position":4,"is_corresponding":false},{"id":230404,"name":"Elias Jabbour","orcid":"0000-0003-4465-6119","position":5,"is_corresponding":false},{"id":232851,"name":"Zeev Estrov","orcid":"0000-0002-1623-3613","position":6,"is_corresponding":false},{"id":109577,"name":"Courtney D. DiNardo","orcid":"0000-0001-9003-0390","position":7,"is_corresponding":false},{"id":232838,"name":"Naveen Pemmaraju","orcid":"0000-0002-1670-6513","position":8,"is_corresponding":false},{"id":232855,"name":"Alessandra Ferrajoli","orcid":"0000-0001-9547-4193","position":9,"is_corresponding":false},{"id":232850,"name":"Nitin Jain","orcid":"0000-0003-0114-8384","position":10,"is_corresponding":false},{"id":230395,"name":"Sa A. Wang","orcid":"0000-0001-9385-9911","position":11,"is_corresponding":false},{"id":772755,"name":"Nadya Jammal","orcid":"0000-0003-1457-178X","position":12,"is_corresponding":false},{"id":232842,"name":"Gautam Borthakur","orcid":"0000-0001-7679-6453","position":13,"is_corresponding":false},{"id":232839,"name":"Kiran Naqvi","orcid":"0000-0002-5511-6153","position":14,"is_corresponding":false},{"id":773247,"name":"Sarah Pelletier","orcid":null,"position":15,"is_corresponding":false},{"id":280568,"name":"Sherry Pierce","orcid":"0000-0002-9542-1558","position":16,"is_corresponding":false},{"id":230405,"name":"Michael Andreeff","orcid":"0000-0002-1144-1958","position":17,"is_corresponding":false},{"id":230408,"name":"Guillermo Garcia‐Manero","orcid":"0000-0002-3631-2482","position":18,"is_corresponding":false},{"id":230406,"name":"Jörge E. Cortes","orcid":"0000-0002-8636-1071","position":19,"is_corresponding":false},{"id":232841,"name":"Tapan M. Kadia","orcid":"0000-0002-9892-9832","position":20,"is_corresponding":false},{"id":772754,"name":"Iman Abou Dalle","orcid":"0000-0002-6520-9134","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-18T23:50:27.616568Z","pmid":"33449377","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}